News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
News Bavarian and BMS press on with Opdivo and cancer vaccine com... BMS hopes combinations will maintain Opdivo lead after setback
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Imbruvica, Opdivo and Praluent gain approvals for Scotland’s... Sanofi steals a march on rivals Amgen
News BMS' Opdivo stumbles in lung cancer, but could still maintai... Analysts expect Opdivo to recover via combination trials
Cancer Ambition trips BMS as Opdivo fails in frontline lung cancer Major setback for BMS, giving Merck's Keytruda the advantage
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
